The main clinico-pathological features of BC with a recognized prognostic value include tumor size, axillary lymph node status, and histological grade, while hormone receptor and HER2 statuses effectively predict the response to hormonal or anti-HER2 target therapies, respectively [1,2,3]. The gene discussed is ERBB2; the disease is breast cancer.